William Hoffman, a director at Inari Medical (TASE:PMCN), Inc. (NASDAQ:NARI), recently executed a series of stock transactions resulting in the sale of shares worth approximately $3.07 million. The sales, completed on November 18, involved a total of 59,000 shares of common stock. The shares were sold at prices ranging from $50.09 to $52.11 per share. Following these transactions, Hoffman holds 501,233 shares in the company. These transactions were conducted under a pre-established Rule 10b5-1 trading plan, which Hoffman adopted in December 2023.
In other recent news, Inari Medical has been making significant strides in both the clinical and financial sectors. The company's PEERLESS trial results demonstrated the superiority of its FlowTriever system over traditional catheter-directed thrombolytics (CDT), potentially adding an additional $150 million to its total addressable market. This revelation, affirmed by Canaccord Genuity's maintained Buy rating, could challenge existing clinical practices and expand Inari Medical's market share.
Despite some skepticism among clinicians, the forthcoming PEERLESS II trial may prove decisive in further bolstering the company's position. Inari Medical's strategic focus on regulatory approvals and market penetration, particularly in high-growth international markets, has also been noted as a key recent development.
Financially, Inari Medical reported a record revenue of $153.4 million in Q3 of 2024, a 21% year-over-year increase. This growth, particularly noticeable in international sales which surged by 76.4%, led the company to raise its full-year revenue outlook to between $601.5 million and $604.5 million. Despite a net loss of $18.4 million, the company is on track for operating profitability in the first half of 2025, underlining its recent advancements and future potential.
InvestingPro Insights
In light of William Hoffman's recent stock transactions, it's worth examining Inari Medical's financial position and market performance. According to InvestingPro data, Inari Medical (NASDAQ:NARI) has a market capitalization of $2.86 billion and is currently trading at a price-to-book ratio of 6.86, which suggests a premium valuation compared to its book value.
Despite the director's significant share sale, Inari Medical has shown strong revenue growth, with a 22.41% increase in the last twelve months, reaching $574.5 million. This growth is complemented by an impressive gross profit margin of 86.82%, indicating efficient cost management in its core operations.
InvestingPro Tips highlight that five analysts have revised their earnings upwards for the upcoming period, potentially signaling positive expectations for the company's future performance. However, it's noted that Inari Medical is not currently profitable, with a negative operating income of $32.02 million in the last twelve months.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights, with 7 more tips available for Inari Medical. These tips could provide valuable context for understanding the company's financial health and market position in light of the recent insider selling activity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.